Sanofi completes acquisition of Synthorx, Inc.
Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash.
"The acquisition of Synthorx perfectly aligns with our R&D strategy, enhancing our position as an emerging leader in the area of oncology and immunology," says Paul Hudson, Chief Executive Officer, Sanofi.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news